American Heart Journal
Volume 158, Issue 5 , Pages 777-783 , November 2009

Prognostic value of B-type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure

  • Robert Kevin Rogers, MD, MSCI

      Affiliations

    • University of Utah, Division of Cardiology, Salt Lake City, UT
    • Corresponding Author InformationReprint requests: Robert Kevin Rogers, MD, Division of Cardiology, University of Utah Health Sciences, 30 North 1900 East, Rm 4A100, Salt Lake City, UT 84132-2401.
    • ,
  • Heidi T. May, PhD, MSPH

      Affiliations

    • Intermountain Health Care, Division of Cardiology, Murray, UT
    • ,
  • Jeffrey L. Anderson, MD

      Affiliations

    • University of Utah, Division of Cardiology, Salt Lake City, UT
    • Intermountain Health Care, Division of Cardiology, Murray, UT
    • ,
  • J. Brent Muhlestein, MD

      Affiliations

    • University of Utah, Division of Cardiology, Salt Lake City, UT
    • Intermountain Health Care, Division of Cardiology, Murray, UT

Received 20 May 2009 ,Accepted 3 September 2009.

References 

  1. Ndrepepa G, Braun S, Schomig A, et al. Accuracy of N-terminal pro-brain natriuretic peptide to predict mortality in various subsets of patients with coronary artery disease. Am J Cardiol. 2007;100:575–578
  2. Palmer BR, Pilbrow AP, Yandle TG, et al. Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol. 2003;41:729–736
  3. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation. 2003;107:2786–2792
  4. Dokainish H, Zoghbi WA, Lakkis NM, et al. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol. 2005;45:1223–1226
  5. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol. 2006;47:85–90
  6. Parsonage WA, Galbraith AJ, Koerbin GL, et al. Value of B-type natriuretic peptide for identifying significantly elevated pulmonary artery wedge pressure in patients treated for established chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2005;95:883–885
  7. Tsutamoto T, Wada A, Sakai H, et al. Relationship between renal function and plasma brain natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2006;47:582–586
  8. Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol. 2007;49:1943–1950
  9. Kragelund C, Gronning B, Kober L, et al. N-terminal pro–B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med. 2005;352:666–675
  10. Richards M, Nicholls MG, Espiner EA, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol. 2006;47:52–60
  11. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014–1021
  12. Kwan G, Isakson SR, Beede J, et al. Short-term serial sampling of natriuretic peptides in patients presenting with chest pain. J Am Coll Cardiol. 2007;49:1186–1192
  13. Lindahl B, Lindback J, Jernberg T, et al. Serial analyses of N-terminal pro–B-type natriuretic peptide in patients with non–ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol. 2005;45:533–541
  14. Androne AS, Hryniewicz K, Hudaihed A, et al. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol. 2004;93:1254–1259
  15. Schnabel R, Lubos E, Rupprecht HJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the AtheroGene study. J Am Coll Cardiol. 2006;47:552–558
  16. Tapanainen JM, Lindgren KS, Makikallio TH, et al. Natriuretic peptides as predictors of non-sudden and sudden cardiac death after acute myocardial infarction in the beta-blocking era. J Am Coll Cardiol. 2004;43:757–763
  17. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–337
  18. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol. 2004;44:1328–1333
  19. Bibbins-Domingo K, Gupta R, Na B, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297:169–176
  20. Shah MR, Hasselblad V, Tasissa G, et al. Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). Am J Cardiol. 2007;100:1427–1433
  21. Cappola TP, Felker GM, Kao WH, et al. Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation. 2002;105:1663–1668
  22. Richards AM, Crozier IG, Yandle TG, et al. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J. 1993;69:414–417
  23. Joung B, Ha JW, Ko YG, et al. Can pro-brain natriuretic peptide be used as a noninvasive predictor of elevated left ventricular diastolic pressures in patients with normal systolic function?. Am Heart J. 2005;150:1213–1219
  24. Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol. 2006;47:742–748
  25. O'Neill JO, Bott-Silverman CE, McRae AT, et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J. 2005;149:363–369
  26. Maeda K, Tsutamoto T, Wada A, et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J. 1998;135:825–832
  27. Taylor JA, Christenson RH, Rao K, et al. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J. 2006;152:1071–1076
  28. Tschope C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26:2277–2284
  29. Murakami Y, Shimada T, Inoue S, et al. New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy. Can J Cardiol. 2002;18:1294–1300
  30. Yamamoto K, Burnett JC, Jougasaki M, et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension. 1996;28:988–994
  31. Ndrepepa G, Braun S, Mehilli J, et al. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol. 2005;95:553–557
  32. Taylor GS, Muhlestein JB, Wagner GS, et al. Implementation of a computerized cardiovascular information system in a private hospital setting. Am Heart J. 1998;136:792–803
  33. Schiller NB, Acquatella H, Ports TA, et al. Left ventricular volume from paired biplane two-dimensional echocardiography. Circulation. 1979;60:547–555
  34. Omland T, Sabatine MS, Jablonski KA, et al. Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol. 2007;50:205–214
  35. Ndrepepa G, Braun S, Niemoller K, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation. 2005;112:2102–2107
  36. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126–1130
  37. Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol. 2007;49:1733–1739
  38. Pfisterer M, Buser P, Rickli H, et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301:383–392
  39. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357–2368
  40. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007;49:1071–1078
  41. Forfia PR, Lee M, Tunin RS, et al. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart. J Am Coll Cardiol. 2007;49:1079–1088
  42. Ni XP, Safai M, Rishi R, et al. Increased activity of cGMP-specific phosphodiesterase (PDE5) contributes to resistance to atrial natriuretic peptide natriuresis in the pregnant rat. J Am Soc Nephrol. 2004;15:1254–1260
  43. Ni XP, Safai M, Gardner DG, et al. Increased cGMP phosphodiesterase activity mediates renal resistance to ANP in rats with bile duct ligation. Kidney Int. 2001;59:1264–1273
  44. Charloux A, Piquard F, Doutreleau S, et al. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest. 2003;33:769–778

PII: S0002-8703(09)00719-4

doi: 10.1016/j.ahj.2009.09.002

American Heart Journal
Volume 158, Issue 5 , Pages 777-783 , November 2009

Article Tools

* Image Usage & Resolution